SCHEMBL4335498

SCHEMBL4335498

NC(=S)N(CCO)N=Cc1ccc(-c2cccc(OC(F)(F)F)c2)o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT1 Q99873 2/20 0.46
ALDH1A1 P00352 7/20 0.40
KDM4E B2RXH2 5/20 0.40
MEN1 O00255 7/20 0.37
KMT2A Q03164 7/20 0.37
MAPT P10636 7/20 0.37
HPGD P15428 4/20 0.37
NPSR1 Q6W5P4 4/20 0.37
LMNA P02545 3/20 0.37
ALOX12 P18054 2/20 0.37
ADORA1 P30542 1/20 0.34
HTT P42858 2/20 0.34
PRKDC P78527 1/20 0.33
PKM P14618 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
FFAR1 O14842 1/20 0.33
FFAR4 Q5NUL3 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4331770 0.91 PRMT1 (0.48) PRMT1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL4331771 0.91 PRMT1 (0.48) PRMT1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL13887391 0.89 PRMT1 (0.55) PRMT1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL4344647 0.88 MAPT (0.38) PRMT1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL4344650 0.88 MAPT (0.38) PRMT1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL4324269 0.87 PRMT1 (0.41) PRMT1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL4324264 0.87 PRMT1 (0.41) PRMT1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL4329136 0.85 KDM4E (0.56) PRMT1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL4329138 0.85 KDM4E (0.56) PRMT1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL4341461 0.82 MAPT (0.49) ALDH1A1KDM4EMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 PRMT1 3363/4885ALDH1A1 1459/4885KDM4E 3010/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 PRMT1 2965/4885ALDH1A1 1173/4885KDM4E 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.